Business Description
Anika Therapeutics Inc
NAICS : 339115
SIC : 3842
ISIN : US0352551081
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.51 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -2.59 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.76 | |||||
Beneish M-Score | -4.21 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.4 | |||||
3-Year EBITDA Growth Rate | -121 | |||||
3-Year Book Growth Rate | -8.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 10 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.17 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 70.86 | |||||
9-Day RSI | 63.77 | |||||
14-Day RSI | 60.55 | |||||
6-1 Month Momentum % | 35.26 | |||||
12-1 Month Momentum % | -5.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.26 | |||||
Quick Ratio | 3.76 | |||||
Cash Ratio | 2.35 | |||||
Days Inventory | 245.5 | |||||
Days Sales Outstanding | 75.62 | |||||
Days Payable | 50.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -0.29 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 61.86 | |||||
Operating Margin % | -15.27 | |||||
Net Margin % | -49.6 | |||||
FCF Margin % | -4.3 | |||||
ROE % | -31.32 | |||||
ROA % | -25.58 | |||||
ROIC % | -10.6 | |||||
ROC (Joel Greenblatt) % | -18.59 | |||||
ROCE % | -8.62 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 23.2 | |||||
Shiller PE Ratio | 38.73 | |||||
PS Ratio | 2.27 | |||||
PB Ratio | 1.78 | |||||
Price-to-Tangible-Book | 1.89 | |||||
EV-to-EBIT | -13.33 | |||||
EV-to-Forward-EBIT | -23.79 | |||||
EV-to-EBITDA | -30.19 | |||||
EV-to-Forward-EBITDA | 40.75 | |||||
EV-to-Revenue | 2.03 | |||||
EV-to-Forward-Revenue | 2 | |||||
EV-to-FCF | -47.01 | |||||
Price-to-Projected-FCF | 1.26 | |||||
Price-to-Median-PS-Value | 0.42 | |||||
Price-to-Net-Current-Asset-Value | 3.6 | |||||
Price-to-Net-Cash | 25.96 | |||||
Earnings Yield (Greenblatt) % | -7.5 | |||||
FCF Yield % | -1.88 | |||||
Forward Rate of Return (Yacktman) % | -10.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Anika Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 154.569 | ||
EPS (TTM) (€) | -5.203 | ||
Beta | 0.32 | ||
Volatility % | 36.75 | ||
14-Day RSI | 60.55 | ||
14-Day ATR (€) | 0.270619 | ||
20-Day SMA (€) | 23.78 | ||
12-1 Month Momentum % | -5.65 | ||
52-Week Range (€) | 15.8 - 25.6 | ||
Shares Outstanding (Mil) | 14.85 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Anika Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Anika Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Anika Therapeutics Inc Frequently Asked Questions
What is Anika Therapeutics Inc(FRA:AKP)'s stock price today?
When is next earnings date of Anika Therapeutics Inc(FRA:AKP)?
Does Anika Therapeutics Inc(FRA:AKP) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |